HAYA Therapeutics key facts
as of Oct 2026- Operator of a precision therapeutics company intended to discover and develop tissue and cell-selective genomic medicines for fibrotic diseases.
- HAYA Therapeutics is valued at approximately $115.5M as of Oct 2026 (last reported valuation).
- It has raised $101.0M; the latest was Later Stage VC ($63.1M) in Apr 2025.
- Notable investors include MassChallenge, Venture Kick, Alexandria Venture Investments, Earlybird Venture Capital, Sofinnova Partners — 18 tracked in total.
- Status: Privately Held (backing).
HAYA Therapeutics's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·The complete investor list: 18 names
- ·Watch HAYA Therapeutics: the Monday email on marks, rounds and moves
HAYA Therapeutics funding rounds
No funding rounds for HAYA Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs HAYA Therapeutics
18+HAYA Therapeutics valuation
HAYA Therapeutics's last reported valuation was $115 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
HAYA Therapeutics investors
18 investors are on record for HAYA Therapeutics, including MassChallenge, Venture Kick, Alexandria Venture Investments and Earlybird Venture Capital.
About HAYA Therapeutics
Operator of a precision therapeutics company intended to discover and develop tissue and cell-selective genomic medicines for fibrotic diseases. The company's therapeutics utilize biopharmaceutical therapy to target a heart-specific regulator of fibrosis and other serious health conditions associated with aging, including cancer, enabling physicians to block myocardial fibrosis and treat heart-related illnesses with efficacy and safety.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2017
- Employees
- 40
- Website
- hayatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.